1
|
Sibuyi NRS, Moabelo KL, Fadaka AO, Meyer S, Onani MO, Madiehe AM, Meyer M. Multifunctional Gold Nanoparticles for Improved Diagnostic and Therapeutic Applications: A Review. NANOSCALE RESEARCH LETTERS 2021; 16:174. [PMID: 34866165 PMCID: PMC8645298 DOI: 10.1186/s11671-021-03632-w] [Citation(s) in RCA: 57] [Impact Index Per Article: 19.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/30/2021] [Accepted: 11/21/2021] [Indexed: 05/07/2023]
Abstract
The medical properties of metals have been explored for centuries in traditional medicine for the treatment of infections and diseases and still practiced to date. Platinum-based drugs are the first class of metal-based drugs to be clinically used as anticancer agents following the approval of cisplatin by the United States Food and Drug Administration (FDA) over 40 years ago. Since then, more metals with health benefits have been approved for clinical trials. Interestingly, when these metals are reduced to metallic nanoparticles, they displayed unique and novel properties that were superior to their bulk counterparts. Gold nanoparticles (AuNPs) are among the FDA-approved metallic nanoparticles and have shown great promise in a variety of roles in medicine. They were used as drug delivery, photothermal (PT), contrast, therapeutic, radiosensitizing, and gene transfection agents. Their biomedical applications are reviewed herein, covering their potential use in disease diagnosis and therapy. Some of the AuNP-based systems that are approved for clinical trials are also discussed, as well as the potential health threats of AuNPs and some strategies that can be used to improve their biocompatibility. The reviewed studies offer proof of principle that AuNP-based systems could potentially be used alone or in combination with the conventional systems to improve their efficacy.
Collapse
Affiliation(s)
- Nicole Remaliah Samantha Sibuyi
- Department of Science and Innovation (DSI)/Mintek Nanotechnology Innovation Centre (NIC) Biolabels Node, Department of Biotechnology, University of the Western Cape, Private Bag X17, Bellville, 7535, South Africa
| | - Koena Leah Moabelo
- Department of Science and Innovation (DSI)/Mintek Nanotechnology Innovation Centre (NIC) Biolabels Node, Department of Biotechnology, University of the Western Cape, Private Bag X17, Bellville, 7535, South Africa
- Nanobiotechnology Research Group, Department of Biotechnology, University of the Western Cape, Bellville, South Africa
| | - Adewale Oluwaseun Fadaka
- Department of Science and Innovation (DSI)/Mintek Nanotechnology Innovation Centre (NIC) Biolabels Node, Department of Biotechnology, University of the Western Cape, Private Bag X17, Bellville, 7535, South Africa
| | - Samantha Meyer
- Department of Biomedical Sciences, Faculty of Health and Wellness Sciences, Cape Peninsula University of Technology, Bellville, South Africa
| | - Martin Opiyo Onani
- Organometallics and Nanomaterials, Department of Chemical Sciences, University of the Western Cape, Bellville, South Africa
| | - Abram Madimabe Madiehe
- Department of Science and Innovation (DSI)/Mintek Nanotechnology Innovation Centre (NIC) Biolabels Node, Department of Biotechnology, University of the Western Cape, Private Bag X17, Bellville, 7535, South Africa.
- Nanobiotechnology Research Group, Department of Biotechnology, University of the Western Cape, Bellville, South Africa.
| | - Mervin Meyer
- Department of Science and Innovation (DSI)/Mintek Nanotechnology Innovation Centre (NIC) Biolabels Node, Department of Biotechnology, University of the Western Cape, Private Bag X17, Bellville, 7535, South Africa.
| |
Collapse
|
2
|
Musielak M, Potoczny J, Boś-Liedke A, Kozak M. The Combination of Liposomes and Metallic Nanoparticles as Multifunctional Nanostructures in the Therapy and Medical Imaging-A Review. Int J Mol Sci 2021; 22:6229. [PMID: 34207682 PMCID: PMC8229649 DOI: 10.3390/ijms22126229] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2021] [Revised: 06/05/2021] [Accepted: 06/06/2021] [Indexed: 12/24/2022] Open
Abstract
Nanotechnology has introduced a new quality and has definitely developed the possibilities of treating and diagnosing various diseases. One of the scientists' interests is liposomes and metallic nanoparticles (LipoMNPs)-the combination of which has introduced new properties and applications. However, the field of creating hybrid nanostructures consisting of liposomes and metallic nanoparticles is relatively little understood. The purpose of this review was to compile the latest reports in the field of treatment and medical imaging using of LipoMNPs. The authors focused on presenting this issue in the direction of improving the used conventional treatment and imaging methods. Most of all, the nature of bio-interactions between nanostructures and cells is not sufficiently taken into account. As a result, overcoming the existing limitations in the implementation of such solutions in the clinic is difficult. We concluded that hybrid nanostructures are used in a very wide range, especially in the treatment of cancer and magnetic resonance imaging. There were also solutions that combine treatments with simultaneous imaging, creating a theragnostic approach. In the future, researchers should focus on the description of the biological interactions and the long-term effects of the nanostructures to use LipoMNPs in the treatment of patients.
Collapse
Affiliation(s)
- Marika Musielak
- Department of Electroradiology, Poznan University of Medical Sciences, 61-701 Poznań, Poland
- Radiobiology Laboratory, Department of Medical Physics, Greater Poland Cancer Centre, 61-866 Poznań, Poland
- Department of Macromolecular Physics, Faculty of Physics, Adam Mickiewicz University, 61-614 Poznań, Poland; (A.B.-L.); (M.K.)
| | - Jakub Potoczny
- Heliodor Swiecicki Clinical Hospital in Poznan, 60-355 Poznań, Poland;
| | - Agnieszka Boś-Liedke
- Department of Macromolecular Physics, Faculty of Physics, Adam Mickiewicz University, 61-614 Poznań, Poland; (A.B.-L.); (M.K.)
| | - Maciej Kozak
- Department of Macromolecular Physics, Faculty of Physics, Adam Mickiewicz University, 61-614 Poznań, Poland; (A.B.-L.); (M.K.)
| |
Collapse
|
3
|
McKernan P, Cassidy B, Woodward A, Battiste J, Drevets D, Harrison R. Anionic phospholipid expression as a molecular target in Listeria monocytogenes and Escherichia coli. Int J Antimicrob Agents 2020; 56:106183. [PMID: 33045345 DOI: 10.1016/j.ijantimicag.2020.106183] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2020] [Revised: 07/02/2020] [Accepted: 10/04/2020] [Indexed: 10/23/2022]
Abstract
This study validates bacterial anionic phospholipids (APs) as a putative molecular target in a novel antibiotic treatment against the Gram-positive bacterium Listeria monocytogenes and the Gram-negative bacterium Escherichia coli. Bacterial AP expression was targeted with its associated protein-ligand partner, annexin A5 (ANXA5). This protein was functionalised with the covalent addition of the antibiotic ampicillin (AMP) and separately with the antibiotic moxifloxacin (MOX). Functionalised ANXA5 serves as a delivery vehicle, directing the antibiotic to bacterial AP expression. The results presented here suggest that this ANXA5-AMP bioconjugate participates in a positive feedback loop where APs, the target of the delivery vehicle ANXA5, are upregulated by the chemotherapeutic payload of the bioconjugate. Importantly, the ANXA5 delivery vehicle is non-toxic to bacterial cells by itself and neither is the ANXA5-antibiotic bioconjugate toxic to human vascular endothelial cells. As measured by the IC50, conjugation to ANXA5 resulted in increasing the antibiotic activity of AMP against L. monocytogenes and E. coli by more than 4 and 3 orders of magnitude, respectively, compared with free AMP, whilst the activity of MOX against L. monocytogenes is increased by 4 orders of magnitude. Given the conservation of AP expression in pathologies such as oncogenesis and other bacterial/viral/parasitic infections, we hypothesise that a therapeutic modality targeting AP expression may be a viable chemotherapeutic strategy in many infectious diseases.
Collapse
Affiliation(s)
- Patrick McKernan
- Department of Neurology, University of Oklahoma Health Sciences Center, 865 Research Parkway, Oklahoma City, OK 73104, USA; Department of Neurosurgery, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA; Department of Radiation Oncology, University of Oklahoma Health Sciences Center Oklahoma City, OK, USA
| | - Benjamin Cassidy
- Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
| | - Alexis Woodward
- School of Biomedical Engineering, University of Oklahoma, 202 W. Boyd St., Norman, OK 73019, USA
| | - James Battiste
- Department of Neurology, University of Oklahoma Health Sciences Center, 865 Research Parkway, Oklahoma City, OK 73104, USA; Stephenson Cancer Center, 800 NE 10th St., Oklahoma City, OK 73104, USA
| | - Douglas Drevets
- Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA; Medical Services, Department of Veterans Affairs Medical Center, 921 NE 13th St., Oklahoma City, OK 73104, USA
| | - Roger Harrison
- Stephenson Cancer Center, 800 NE 10th St., Oklahoma City, OK 73104, USA; School of Chemical, Biological and Materials Engineering, University of Oklahoma, 100 E. Boyd St., Norman, OK 73019, USA.
| |
Collapse
|